Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.99 USD
Change Today +0.12 / 4.18%
Volume 717.9K
RIGL On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

rigel pharmaceuticals inc (RIGL) Snapshot

Open
$2.87
Previous Close
$2.87
Day High
$3.08
Day Low
$2.81
52 Week High
04/27/15 - $5.20
52 Week Low
10/22/14 - $1.56
Market Cap
264.6M
Average Volume 10 Days
560.3K
EPS TTM
$-0.86
Shares Outstanding
88.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RIGEL PHARMACEUTICALS INC (RIGL)

rigel pharmaceuticals inc (RIGL) Related Businessweek News

No Related Businessweek News Found

rigel pharmaceuticals inc (RIGL) Details

Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. It is developing fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura and Phase II clinical trials for IgA nephropathy; R348, a topical JAK/SYK inhibitor that is in Phase II clinical trials for the treatment of dry eye in ocular graft-versus-host disease; and two oncology product candidates in Phase I development. The company has a license agreement with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; a license agreement with BerGenBio AS for the development and commercialization of an oncology program; a collaboration agreement with Daiichi Sankyo to pursue research related to a specific target from a class of drug targets called ligases that control cancer cell proliferation through protein degradation; and a collaboration agreement with Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies. Rigel Pharmaceuticals, Inc. was founded in 1996 and is based in South San Francisco, California.

127 Employees
Last Reported Date: 03/3/15
Founded in 1996

rigel pharmaceuticals inc (RIGL) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $551.7K
Co-Founder, President of Discovery & Research...
Total Annual Compensation: $559.6K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $441.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $521.3K
Executive Vice President of Corporate Affairs...
Total Annual Compensation: $475.5K
Compensation as of Fiscal Year 2014.

rigel pharmaceuticals inc (RIGL) Key Developments

Rigel Pharmaceuticals Mulls Acquisitions

Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL) is seeking acquisitions. Rigel Pharmaceuticals announced a follow-on equity offering in the amount of $30.00 million and said in prospectus, “We may also use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to our own, although we have no commitments or agreements with respect to any acquisitions as of the date of this prospectus supplement.”

Rigel Pharmaceuticals, Inc. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Rigel Pharmaceuticals, Inc. announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported contract revenues from collaborations of $5,184,000, which was all related to collaboration with Bristol-Myers Squibb. It was comprised of $4.8 million of amortization of the $30 million upfront payment and $350,000 of research reimbursement. Loss from operations was $13,974,000 compared with $25,456,000 for the same period a year ago. Net loss was $13,912,000 or $0.16 per basic and diluted share compared with $25,391,000 or $0.29 per basic and diluted share for the same period a year ago. For the six months, the company reported contract revenues from collaborations of $7,362,000. Loss from operations was $32,215,000 compared with $47,841,000 for the same period a year ago. Net loss was $32,105,000 or $0.36 per basic and diluted share compared with $47,694,000 or $0.54 per basic and diluted share for the same period a year ago.

Rigel Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 04, 2015

Rigel Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RIGL:US $2.99 USD +0.12

RIGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $2.71 USD +0.06
ArQule Inc $1.76 USD 0.00
CrystalGenomics Inc 13,400 KRW +400.00
CTI BioPharma Corp $1.60 USD +0.03
Progenics Pharmaceuticals Inc $7.67 USD -0.16
View Industry Companies
 

Industry Analysis

RIGL

Industry Average

Valuation RIGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.9x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RIGEL PHARMACEUTICALS INC, please visit www.rigel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.